Harris, Sarah http://orcid.org/0000-0001-9433-7496
Feagan, Brian G.
Hanauer, Stephen
Vermeire, Severine
Ghosh, Subrata
Yan, Jim
Wu, Chun
Hu, Yanhua
Maddux, Rachel
Wolf, Douglas C.
D’Haens, Geert
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn’s Disease
https://doi.org/10.1007/s10620-024-08391-z
Next generation of small molecules in inflammatory bowel disease
https://doi.org/10.1136/gutjnl-2016-312912
Article History
Received: 5 December 2023
Accepted: 13 March 2024
First Online: 3 April 2024
Declarations
:
: Sarah Harris, Chun Wu, Yanhua Hu, and Rachel Maddux: employees and/or shareholders of Bristol Myers Squibb. Brian G. Feagan: consulted for AbbVie, ActoGeniX, Albireo, Amgen, AstraZeneca, Avaxia Biologics, Baxter, Biogen Idec, Boehringer Ingelheim, Bristol Myers Squibb, Calypso, Celgene, Elan, Eli Lilly, enGene, Ferring Pharmaceuticals, Roche/Genentech, gIcare Pharma, Gilead, Given Imaging, GlaxoSmithKline, Ironwood, Janssen, Johnson & Johnson, Lexicon, Merck, Millennium, Nektar, Novo Nordisk, Pfizer, Prometheus Laboratories, Protagonist, Sanofi, and UCB; and is a director at Robarts Clinical Trials. Stephen Hanauer: consulted for AbbVie, Actavis, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Celgene, Ferring Pharmaceuticals, Janssen, Merck, Pfizer, Salix, Sanofi-Aventis, Shire, and UCB. Severine Vermeire: received research funding from AbbVie, Galapagos, Johnson & Johnson, Pfizer, and Takeda; and has received consulting and/or speaking fees from AbbVie, Abivax, AbolerIS Pharma, AgomAb, Alimentiv, Arena, AstraZeneca, Avaxia, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, CVasThera, Cytoki Pharma, Dr Falk Pharma, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline, Hospira, IMIDomics, Janssen, Johnson & Johnson, Materia Prima, MiroBio, Morphic Therapeutic, MRM Health, MSD, Mundipharma, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillotts Pharma AG, and Zealand. Subrata Ghosh: received research funding from AbbVie; has served as a speaker for AbbVie and MSD; and has consulted for AbbVie, Bristol Myers Squibb, Celgene, Janssen, Novo Nordisk, and Pfizer. Jim Yan: employee and shareholder of Laboratory Corporation of America Holdings. Douglas C. Wolf: received honoraria as a speaker, consultant, and/or advisory board member from AbbVie, Arena, Celgene/Bristol Myers Squibb, Janssen, Pfizer, Prometheus, Takeda, and UCB. Geert D’Haens: served as an advisor for AbbVie, Agomab Therapeutics, Alimentiv, Applied Molecular Therapeutics, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Cytoki, Eli Lilly, Exeliom Biosciences, Ferring, Galapagos, GlaxoSmithKline, Gossamer Bio, Immunic, Johnson & Johnson, Pfizer, Polpharma, ProciseDx, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Seres, Takeda, Tillotts, and Versant; and received speaker fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Johnson & Johnson, Pfizer, Takeda, and Tillotts.